MartÃn Roldán, A.; Sánchez Suárez, M.D.M.; Alarcón-Payer, C.; Jiménez Morales, A.; Puerta Puerta, J.M.
A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. Pharmaceutics 2023, 15, 1363.
https://doi.org/10.3390/pharmaceutics15051363
AMA Style
MartÃn Roldán A, Sánchez Suárez MDM, Alarcón-Payer C, Jiménez Morales A, Puerta Puerta JM.
A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. Pharmaceutics. 2023; 15(5):1363.
https://doi.org/10.3390/pharmaceutics15051363
Chicago/Turabian Style
MartÃn Roldán, Alicia, MarÃa Del Mar Sánchez Suárez, Carolina Alarcón-Payer, Alberto Jiménez Morales, and José Manuel Puerta Puerta.
2023. "A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia" Pharmaceutics 15, no. 5: 1363.
https://doi.org/10.3390/pharmaceutics15051363
APA Style
MartÃn Roldán, A., Sánchez Suárez, M. D. M., Alarcón-Payer, C., Jiménez Morales, A., & Puerta Puerta, J. M.
(2023). A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. Pharmaceutics, 15(5), 1363.
https://doi.org/10.3390/pharmaceutics15051363
